Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Glucose Monitoring, Other Feb 07 | 2022Diamyd to Initiate Ph3 DIAGNODE-3 Trial in Europe; First Patient Dosed with CRISPR and ViaCyte's VCTX210 in Ph1 Trial; Know Labs Bio-RFID Device Receives IRB ApprovalPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Insulin Delivery, SGLT2i Feb 04 | 2022Novo Q4 '21 London Earnings; Sanofi and Regeneron Q4 ‘21 and FY ‘21 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Other, SGLT2i Feb 03 | 2022Lannett, Merck, Roche, and BD Q4 ‘21 and FY ’21 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Other, SGLT2i Feb 03 | 2022Lilly Q4 ‘21 and FY ‘21 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other Feb 02 | 2022Novo Q4 and FY ’21 Earnings UpdatePurchase Blast
$599
Posted in: Other Jan 31 | 2022Pfizer and Ionis Discontinue Vupanorsen in Dyslipidemia; Glooko Acquires xbird; Madrigal Announces Positive Ph3 MAESTRO-NAFLD-1 Topline ResultsPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 28 | 2022Insulet Omnipod 5 Receives FDA Clearance; BI/Lilly’s Jardiance HFpEF Indication Receives Positive CHMP Opinion; Provention Hosts Teplizumab BLA Resubmission Call with Investors; Lilly to Invest $1.5B in Two New Manufacturing SitesPurchase Blast
$599
Posted in: GLP-1RA, Other Jan 27 | 2022Provention Bio to Resubmit Teplizumab BLA; Novo’s Wegovy Shortage Resolution Appears on Track; Vertex Q4 ’21 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Jan 26 | 2022Libre 3 Filed as iCGM in US; Abbott Q4 '21 Earnings Update; FDA Warns Lilly for Misleading Trulicity Instagram PromoPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 25 | 2022J&J Q4 '21 Earnings Update; Glytec Partners with Nebraska Medicine; Daewoong Pharma Announces Positive Ph3 Enavogliflozin Results in T2DMPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, Other, SGLT2i Jan 24 | 2022Jardiance HFpEF Indication Extension Up for Adoption; January 24-27 CHMP AgendaPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Jan 21 | 2022FDA Approves Lannett’s Bs-glargine IND; Biocon CY Q4 '21 (FY Q3 '22) Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Jan 20 | 2022Arecor Initiates Ph1 Ultra-Rapid Insulin Trial in T1DMPurchase Blast
$599
Posted in: Basal Insulin, Other Jan 19 | 2022Viatris Recalls One Batch of Non-interchangeable Semglee Prefilled Pens; Dario Hosts 2022 Investor WebinarPurchase Blast
$599
Posted in: Other Jan 18 | 2022Lilly Partners with Abbisko Therapeutics and Evotec; Novo Partners with EraCal Therapeutic; Fractyl Announces Initial Interim Feasibility DataPurchase Blast
$599
Posted in: Other Jan 14 | 2022Can Michael Davidson Strike Gold Again with NewAmsterdam’s CETPi?Purchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i Jan 13 | 2022JPM 2022 Day 4: Lexicon and Esperion; Imcyse Reports Positive Data from Interim Analysis of Ph2 IMPACT Trial; vTv Therapeutics Provides Update on TTP399 Development; Nemaura Launches Miboko to Employers and InsurersPurchase Blast$599
Posted in: Bolus Insulin, Other Jan 12 | 2022JPM 2022 Day 3: Akebia, Ionis, and Hikma; Oramed Provides Updates on Ph3 Oral Insulin ProgramPurchase Blast$599
Posted in: GLP-1RA, Glucose Monitoring, Other Jan 11 | 2022JPM 2022 Day 2: LLY, ABT, AMRN, SNY, AMGN, RHHBY, and TEVAPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
